Performance of a new steroid-eluting coronary sinus lead designed for left ventricular pacing.
The Ventak CHF/CONTAK CD Biventricular Pacing Study is a prospective randomized trial to examine the safety and efficacy of biventricular (BV) pacing in patients with standard indications for an ICD, symptomatic heart failure, a LVEF < or = 0.35, and a QRS > or = 120 ms. Patients underwent implantation of a BV pacing and sensing system with backup defibrillation capability, which includes a steroid-eluting coronary venous lead that is advanced into the coronary venous vasculature by over-the-wire techniques. LV pacing threshold, BV impedance, and BV R wave amplitude were measured in 58 consecutive patients. Using a percutaneous over-the-wire insertion technique, steroid-eluting coronary venous leads were associated with satisfactory mean LV pacing threshold, BV impedance, and BV R wave amplitude acutely up to 4 months after implantation. Pacing threshold stabilized 2 weeks after lead implantation and sensing threshold remained stable from the time of implant.
Achtelik
M
M
University Hospital Herne, Herne, Germany. Michael.Achtelik@ruhr-uni-bochum.de
Bocchiardo
M
M
Trappe
H J
HJ
Gaita
F
F
Lozano
I
I
Niazi
I
I
Gold
M
M
Yong
P
P
Duby
C
C
D006348:Cardiac Surgical Procedures / Q000379:methods; D003331:Coronary Vessels / Q000601:surgery*; D004343:Drug Implants; D004869:Equipment Safety; D005060:Europe; D005500:Follow-Up Studies; D006333:Heart Failure / Q000150:complications / Q000628:therapy*; D006801:Humans; D010138:Pacemaker, Artificial / Q000009:adverse effects; D011446:Prospective Studies; D012684:Sensory Thresholds; D013256:Steroids / Q000008:administration & dosage*; D013318:Stroke Volume; D016896:Treatment Outcome; D014481:United States; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000628:therapy*
D004343:Drug Implants; D013256:Steroids